ALBINTERFERON ALFA-2B

Summary

Albinterferon Alfa-2B (CHEMBL2107842) is a phase-3 clinical-stage unknown (ATC L03AB12); indicated across 4 conditions including chronic hepatitis c virus infection and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: L03AB12
• Indications: 4 conditions
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107842
Name	ALBINTERFERON ALFA-2B
Type	Unknown
Max phase	3
ATC	L03AB12

Also known as: Albinterferon alfa-2b, Albuferon, Interferon-alfa-2b, ALBINTERFERON ALFA-2B

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
neoplasm	3	MONDO:0005070	EFO:0000616
hepatitis C virus infection	2	MONDO:0005231	EFO:0003047
chronic hepatitis B virus infection	1	MONDO:0005366	EFO:0004239

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE2	5
PHASE4	1
PHASE1/PHASE2	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00375661	PHASE4	COMPLETED	Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
NCT00059826	PHASE2	COMPLETED	Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer
NCT00097435	PHASE2	COMPLETED	A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
NCT00115908	PHASE2	COMPLETED	A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1
NCT00656006	PHASE2	COMPLETED	A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
NCT00964665	PHASE1/PHASE2	TERMINATED	Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects
NCT02737046	PHASE2	COMPLETED	Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
NCT00489385	PHASE1	COMPLETED	An Open Label Non-Randomized Dose Escalating Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals
NCT00216775	Not specified	COMPLETED	Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).